Melanoma targeted therapies dabrafenib and trametinib cross the placental barrier in ex vivo human placental perfusions - 17/10/25
Doi : 10.1016/j.jaad.2025.07.045
Estelle Heggarty, MD, MSc a, b, ⁎ 
, David Combarel, PharmD c, d, Hadia Moindjie, PhD b, François Vialard, MD, PhD e, Laure Benoit, MD, MSc a, b, Yoann Rodriguez, MSc b, Stanislas Grassin-Delyle, PhD f, Elodie Lamy, PhD f, Olivier Mir, MD, PhD g, Angelo Paci, PharmD, PhD c, d, Paul Berveiller, MD, PhD a, b
, David Combarel, PharmD c, d, Hadia Moindjie, PhD b, François Vialard, MD, PhD e, Laure Benoit, MD, MSc a, b, Yoann Rodriguez, MSc b, Stanislas Grassin-Delyle, PhD f, Elodie Lamy, PhD f, Olivier Mir, MD, PhD g, Angelo Paci, PharmD, PhD c, d, Paul Berveiller, MD, PhD a, b a Department of Obstetrics and Gynecology, Poissy Hospital, Poissy, France
b Mixed Research Unit 1198, RHuMA Team, Paris Saclay University, UVSQ, INRAE, BREED, Jouy-en Josas, France
c Pharmacology Department, Gustave Roussy Institute, Villejuif, France
d Pharmacokinetic Department, Faculté de Pharmacie, Paris-Saclay University, Gif-sur-Yvette, France
e Paris Saclay University, UFR Simone Veil Santé, Saint-Quentin en Yvelines Université, Montigny-Le-Bretonneux, France
f Mixed Research Unit 1173, Department of Health Biotechnology, INSERM, Paris Saclay University, Montigny-le-Bretonneux, France
g Oncology Unit, Oncology Department, Gustave Roussy Institute, Villejuif, France
∗Correspondence to: Estelle Heggarty, MD, MSc, Department of Obstetrics and Gynecology, Poissy Hospital, 10 rue du Champ Gaillard, Poissy, 78300, FranceDepartment of Obstetrics and GynecologyPoissy Hospital10 rue du Champ GaillardPoissy78300France
Key words : dabrafenib, melanoma, placenta, placental barrier, placental transfer, preclinical data, pregnancy, pregnancy-associated melanoma, targeted therapies, trametinib
| Funding sources: This study was funded by a public grant from ARS IDF (Agence Régionale de Santé d’Ile de France) and by the IRSF (Institut de Recherche en Santé de la Femme) charity. Neither sponsor had influence in study design, data collection or analysis. |
|
| This paper's findings were presented at the 2024 Society for Maternal-Fetal Medicine Pregnancy Meeting in National Harbor, MD on 2/13/2024 (oral communication). |
|
| IRB approval status: Reviewed and approved by Comité de Protection des Personnes Ile de France V, study number 10100529055. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 93 - N° 5
P. 1337-1339 - novembre 2025 Retour au numéro
Article précédent
- Glucagon-like peptide-1 receptor agonists in the adjunctive treatment of patients with hidradenitis suppurativa: A systematic review
- Abizairie Sánchez-Feliciano, Henry Herrera, Alexandra Charrow, John S. Barbieri
- Impact of different dressings on scars after breast surgery
- Anna Kasielska-Trojan, Bogusław Antoszewski, Marta Fijałkowska
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?